Large-scale SPPS capacity in Braine-l’Alleud starts production
See media releaseInnovation for large-scale peptide production
See our presentation at a recent broker event related to GLP-1
Download presentationCreating the future in peptides
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usAhead on green peptide chemistry
Together we improve process performance while reducing the environmental footprint
Learn moreMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial
24 Apr 2025 - Sweden, 24 April 2025 – Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical […]
Read morePolyPeptide announces results of the annual General Meeting 2025
9 Apr 2025 - Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read more